Danaparoid in the prevention of thromboembolic complications

Annals of Pharmacotherapy

Volumn 31, Issue 7-8, 1997, Pages 876-887

  Skoutakis, Vasilios A ^a,b  

^a National Pharmacotherapy Institute   (United States)

^b Nashville Clinical Education Center and Statewide   (United States)

Author keywords

Danaparoid; Thromboembolism

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ANISINDIONE; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; DANAPAROID; DEXTRAN; DICOUMAROL; DIHYDROERGOTAMINE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; PHENINDIONE; REVIPARIN; TINZAPARIN; WARFARIN;

BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; HEART FAILURE; HIP SURGERY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0030824755     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100715     Document Type: Review

References (81)

1. Sevitt S, Gallagher NG. Prevention of venous thrombosis and pulmonary embolism in injured patients. Lancet 1959;2:981-9.
2. NIH Consensus Conference. Prevention of venous thrombosis and pulmonary embolism. JAMA 1986;256:744-9.
3. Clagett GP, Anderson FA Jr, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995;108(suppl):312S-34.
4. O'Meara PM, Kaufman EE. Prophylaxis for venous thromboembolism in total hip arthroplasty: a review. Orthopedics 1990;13:173-8.
5. Meuleman DG. Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models. Thromb Haemost 1987;58:376-80.
6. Meuleman DG. Orgaran (Org 10172): its pharmacological profile in experimental models. Haemostasis 1992;22:58-65.
7. Ockelford PA, Carter CJ, Hirsh J. In vivo activity of a new heparinoid. Pathology 1985;17:78-81.
8. Anderson FA Jr, Wheeler HB. Venous thromboembolism: risk factors and prophylaxis. Clin Chest Med 1995;16:235-51.
9. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worchester DVT Study. Arch Intern Med 1991;151:933-8.
10. Alpert JS, Dalen JE. Epidemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis 1994;36:417-22.
11. Wessler S, Yin ET. On the mechanism of thrombosis. Prog Hematol 1969;6:201-32.
12. Cronan JJ. Venous thromboembolic disease: the role of US. Radiology 1993;186:619-30.
13. Scharfstein J, Loscalzo J. Molecular approaches to antithrombotic therapy. Hosp Pract 1992;27:77-86.
14. Merli GJ. Deep vein thrombosis and pulmonary embolism prophylaxis in orthopedic surgery. Med Clin North Am 1993;77:397-411.
15. Wheeler HB, Anderson FA Jr. Diagnostic methods for deep vein thrombosis. Haemostasis 1995;25:6-26.
16. Kearon C, Hirsh J. The diagnosis of pulmonary embolism. Haemostasis 1995;25:72-87.
17. Weinman EE, Salzman EW. Deep-vein thrombosis. N Engl J Med 1994; 331:1630-41.
18. Hoek JA, Nurmohamed MT, Hamelynck KJ, Marti RK, Knipscheer HC, Ten Gate H, et al. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost 1992;67:28-32.
19. Hull RD, Raskob GE. Current concepts review: prophylaxis of venous thromboembolic disease following hip and knee surgery. J Bone Joint Surg 1986;68:146-50.
20. Fareed J. Venous thromboprophylaxis in the 1990s: a perspective. Semin Thromb Hemostasis 1991;17:317-21.
21. Tapson VF, Hull RD. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin. Clin Chest Med 1995;16: 281-94.
22. Hirsh J. Heparin. N Engl J Med 1991;324:1565-74.
23. Beisaw N, Comerota AJ, Groth HE, Merli GJ, Weitz HH, Zimmerman RC, et al. Dihydroergotamine/heparin in the prevention of deep-vein thrombosis after total hip replacement. A controlled, prospective, randomized, multicenter trial. J Bone Joint Surg 1988;70:2-10.
24. Haas S, Haas P. Efficacy of low molecular weight heparins: an overview. Semin Thromb Hemost 1993;19(suppl 1):101-6.
25. Jorgensen LN, Wille-Jorgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg 1993;80:689-704.
26. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152-6.
27. Mohr DN, Silverstein MD, Murtaugh PA, Harrison JM. Prophylactic agents for venous thrombosis in elective hip surgery: meta-analysis of studies using venographic assessment. Arch Intern Med 1993;153:2221-8.
28. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-6.
29. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994;271: 1780-5.
30. Stiekema JCJ, van Griensven JMT, van Dinther TG, Cohen AF. A crossover comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan. Br J Clin Pharmacol 1993;36:51-6.
31. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991;324:1865-75.
32. Poller L. Therapeutic ranges for oral anticoagulation in different thromboembolic disorders. Ann Hematol 1992;64:52-9.
33. Bradbrook D, Magnani HN, Moelker HCT, Morrison PJ, Robinson J, Rogers HJ, et al. Org 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol 1987;23:667-75.
34. Danhof M, de Boer A, Magnani HN, Stiekema JCJ. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Hemostasis 1992;22: 73-84.
35. Nurmohamed MT, Fareed J, Hoppensteadt D, Walenga JM, Ten Cate JW. Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan. Semin Thromb Hemost 1991;17(suppl 2):205-13.
36. Gordon DL, Linhardt R, Adams HP Jr. Low-molecular-weight heparins and heparinoids and their use in acute or progressing ischemic stroke. Clin Neuropharmacol 1990;13:522-43.
37. Meuleman DG, Hobbelen PMJ, Van Dedem G, Moelker HCT. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models. Thromb Res 1982;27:353-63.
38. Ofosu FA. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombi III (Org 10849). Haemostasis 1992;22:66-72.
39. Van Dinther TG, Hol F, Meuleman DG. Effect of various heparin(oid)s on heparin cofactor IJ mediated anti-thrombin activity and inhibition of thrombin generation in vitro (abstract). Thromb Haemost 1987;58:423.
40. Boneu B, Buchanan MR, Cade JR, Van Ryn J, Femandez FF, Ofosu FA, et al. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. Thromb Res 1985;40:81-9.
41. Vogel GMT, van Amsterdam RGM, Kop WJ, Meuleman DG. Pentasac-charide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. Thromb Haemost 1993;69:29-34.
42. Mikhailidis DP, Barradas MA, Mikhailidis AM, Magnani H, Dandona P. Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br J Clin Pharmacol 1984;17:43-8.
43. Mikhailidis DP, Fonseca VA, Barradas MA, Jeremy JY, Dandona P. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172). Br J Clin Pharmacol 1987;24:415-24.
44. Zammit A, Dawes J. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma. Thromb Haemost 1994;71:759-67.
45. Stiekema JCJ, Wijnand HP, van Dinther TG, Moelker HCT, Dawes J, Vinchenzo A, et al. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers. Br J Clin Pharmacol 1989;27:39-48.
46. Cade JF, Wood M, Magnani HN, Westlake GW. Early clinical experience of a new heparinoid, Org 10172, in prevention of deep venous thrombosis. Thromb Res 1987;45:497-503.
47. Gerhart TN, Yen HS, Robertson LK, Lee MA, Smith M, Salzman EW. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial. J Bone Joint Surg 1991; 73A:494-502.
48. Turpie AGG, Hirsh J, Jay RM, Andrew M, Hull RD, Levine MN, et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987;1:523-6.
49. Turpie AGG, Gent M, Cote R, Levine MN, Ginsberg JS, Powers PJ, et al. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study. Ann Intern Med 1992;117:353-7.
50. de Boer A, Stiekema JCJ, Danhof M, Breimer DD. The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172. Br J Clin Pharmacol 1991;32:23-9.
51. Massey EW, Biller J, Davis JN, Adams HP Jr, Marler JR, Goldstein LB, et al. Large-dose infusions of heparinoid ORG 10172 in ischemic stroke. Stroke 1990;21:1289-92.
52. Gent M, Hirsh J, Ginsberg JS, Powers PJ, Levine MN, Geerts WH, et al. Low-molecular-weight heparinoid Orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation 1996;93:80-4.
53. Org 10172 hip joint replacement report, research protocol 004-023. West Orange, NJ: Organon Inc., 1994.
54. Bergqvist D, Kettunen K, Fredin H, Fauno P, Suomalainen O, Soimakallio S, et al. Thromboprophylaxis in patients with hip fractures: a prospective, randomized, comparative study between Org 10172 and dextran 70. Surgery 1991;109:617-22.
55. Leyvraz P, Bachmann F, Bohnet J, Breyer HG, Estoppey D, Haas S, et al. Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine. Br J Surg 1992;79:911-4.
56. de Valk HW, Banga JD, Wester JWJ, Brouwer CB, van Hessen MWJ, Meuwissen OJAT, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med 1995; 123:1-9.
57. Biller J, Massey EW, Marler JR, Adams HP Jr, Davis JN, Bruno A, et al. A dose escalation study of Org 10172 (low molecular weight heparinoid) in stroke. Neurology 1989;39:262-5.
58. Callus A, Cade J, Ockelford P, Hepburn S, Maas M, Magnani H, et al. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. Thromb Haemost 1993;70:562-7.
59. Henny CP, Ten Cate JW, van Bronswijk H, Ten Gate H, Surachno S, Wilmink JM, et al. Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications. Lancet 1983;I:890-3.
60. Henny CP, Ten Cate H, Surachno S, Slevens P, Buller HR, den Hartog M, et al. The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis. Thromb Haemost 1985;54:460-2.
61. von Bonsdorff M, Stiekema J, Harjanne A, Alapiessa U. A new low molecular weight heparinoid Org 10172 as anticoagulant in hemodialysis. Int J Artif Organs 1990;13:103-8.
62. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia: know what to do. Med North Am 1995;6:942-9.
63. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
64. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984;100:535-40.
65. Laster J, Cikrit D, Walker N, Silver D. The heparin-induced thrombocytopenia syndrome: an update. Surgery 1987;102:763-70.
66. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70:554-61.
67. Chong BH, Ismail F, Cade J, Gallus AS, Gordon S, Chesterman CN. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989;73:1592-6.
68. Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Haemostasis 1992;22:85-91.
69. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 1992; 67:545-9.
70. Oriel TL, Gockerman JP, Califf RM, McCann RL, O'Connor CM, Metzler DM, et al. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. Thromb Haemost 1992;67:292-6.
71. Rowlings PA, Mansberg R, Rozenberg MC, Evans S, Murray B. The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis. Aust N Z J Med 1991;21:52-4.
72. Kleinschmidt S, Seyfert UT. Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice. Angiology 1995;46:37-44.
73. Kikta MJ, Keller P, Humphrey PW, Silver D. Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome? Surgery 1993;114:705-10.
74. Makhoul RG, Greenberg CS, McCann RL. Heparin-induced thrombocytopenia and thrombosis: a serious clinical problem and potential solution. J Vase Surg 1986;4:522-8.
75. Package insert. Orgaron (danaparoid). Auckland, New Zealand: Pharmaco Ltd., 1996.
76. Hirsh J. Overview of low molecular weight heparins and heparinoids: basic and clinical aspects. Aust N Z J Med 1992;487-95.
77. Stiekema JCJ, Wijnand HP, Ten Cate H, Ten Gate JW, Harenberg J, Egberts JFM, et al. Partial in vivo neutralisation of plasma anticoagulant effects of Lomoparan (Org 10172) by protamine chloride. Thromb Res 1991;63:157-67.
78. De Boer A, Danhof M, Cohen AF, Magnani HN, Breimer DD. Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers. Thromb Haemost 1991; 66:202-7.
79. Stiekema JCJ, de Boer A, Danhof M, Kroon C, Broekmans AW, van Dinther TG, et al. Internation of the combined medication with the new low-molecular-weight heparinoid Lomoparan (Org 10172) and acenocoumarol. Haemostasis 1990;20:136-46.
80. de Boer A, Stiekema JC, Danhof M, Breimer DD. Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers. J Clin Pharmacol 1991;31:611-7.
81. Ten Cate H, Henny CP, Ten Cate JW, Buller HR, Mooy MC, Surachno S, et al. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients. Thromb Res 1985;39:211-22.